Box–Behnken design aided optimization and validation of developed reverse phase HPLC analytical method for simultaneous quantification of dolutegravir sodium and lamivudine co‐loaded in nano‐liposomes. Issue 15 (16th June 2021)

• Record Type: Journal Article
• Authors: Mutalik, Sadhana P; Mullick, Prashansha; Pandey, Abhijeet; Kulkarni, Smita S.; Mutalik, Srinivas
• Is Part Of: Journal of separation science. Volume 44:Issue 15(2021)
• Page Start: 2917
• Page End: 2931
• Publication Date: 2021-06-16
• Subjects: Box–Behnken design -- dolutegravir -- lamivudine -- liquid chromatography -- nano‐liposomes; Separation (Technology) -- Periodicals; Chromatographic analysis -- Periodicals; 543.089
• DOI: 10.1002/jssc.202100152
• Languages: English
• ISSNs: 1615-9306

Abstract

Abstract: A stability‐indicating reversed‐phase high‐performance liquid chromatography method for simultaneous estimation of dolutegravir sodium and lamivudine encapsulated in the nanoliposomal formulation was developed. The chromatographic parameters namely, organic phase ratio, flow rate, and sample injection volume were selected as independent factors and were optimized by multivariate Box–Behnken design. Responses analyzed were retention time, peak area, and resolution. The optimized chromatographic method with Hypersil BDS C8 CN column as stationary phase and methanol and acetonitrile mixture and acidified Milli‐Q water (pH 2.8, adjusted with 0.02% v/v orthophosphoric acid) as the mobile phase in an isocratic elution mode was validated according to parameters of International Conference on Harmonization Q1(R2) guidelines. The validated reversed‐phase high‐performance liquid chromatography method exhibited specificity for both dolutegravir sodium and lamivudine in the presence of degradation products as well as the liposomal matrix. This method was effectively utilized to determine the amount of drug entrapped and drug loading efficiency of dolutegravir sodium and lamivudine in a nano‐liposomal formulation.